Therefore, NCCN, American Society of Clinical Oncology, European Society for Medical Oncology, and other major guidelines and expert consensus groups suggest that HER-2+ breast cancer treatments include trastuzumab-based NAC regimens. Here, ERBB2 is linked to breast cancer.